These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 1360275)
1. Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. Baguley BC; Finlay GJ; Ching LM Oncol Res; 1992; 4(7):267-74. PubMed ID: 1360275 [TBL] [Abstract][Full Text] [Related]
2. [Poisons of DNA topoisomerases I and II]. Charcosset JY; Soues S; Laval F Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein. Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226 [TBL] [Abstract][Full Text] [Related]
6. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
7. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Finlay GJ; Riou JF; Baguley BC Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277 [TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of multidrug resistance in cancer treatment. Harris AL; Hochhauser D Acta Oncol; 1992; 31(2):205-13. PubMed ID: 1352455 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
12. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
14. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells. de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302 [TBL] [Abstract][Full Text] [Related]
16. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Nitiss JL; Vilalta PM; Wu H; McMahon J Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059 [TBL] [Abstract][Full Text] [Related]
17. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509 [TBL] [Abstract][Full Text] [Related]
19. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Friche E; Danks MK; Schmidt CA; Beck WT Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312 [TBL] [Abstract][Full Text] [Related]
20. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure. Matsumoto Y; Takano H; Nagao S; Fojo T Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]